InVivoMAb anti-mouse/human HER2 (domain I) (CD340)

About InVivoMAb anti-mouse/human HER2 (domain I) (CD340)

The H2Mab-304 monoclonal antibody reacts with domain I of mouse and human receptor tyrosine-protein kinase erbB-2 (ERBB2), also known as human epidermal growth factor receptor 2 (HER2), CD340, or NEU. HER2 is a 185 kDa transmembrane receptor tyrosine kinase that is part of the EGFR family. The HER2 receptor contains a cytoplasmic tyrosine kinase domain, multiple cytoplasmic tyrosine residues that function as phosphorylation sites, a hydrophobic single-pass transmembrane domain, and an extensive extracellular domain (ECD) subdivided into four functional domains (I, II, III, and IV). Domains I and III facilitate ligand binding, domain II reinforces protein-protein interactions during dimerization, and domain IV stabilizes interactions between HER2 and its dimerization partner. HER2 lacks identified ligands; nonetheless, its homodimerization (HER2/HER2) and heterodimerization (EGFR/HER2, HER2/HER3, and HER2/HER4) facilitate HER2 activation, subsequently modulating downstream signaling pathways, including PI3K/Akt/mTOR and NF-kB. HER2 is essential for cell proliferation, survival, and differentiation, and in cancers, dysregulated HER2 signaling or its overexpression often correlates with aggressive tumor growth. In addition to breast cancer, HER2 is overexpressed in gastric, gastroesophageal, colorectal, lung, endometrial, and ovarian cancers.